Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma

Use of preoperative ultrasonography as guidance for neck dissection in patients with papillary thyroid carcinoma

“…However, US had specificities >93% for detecting metastases in all subsites of the central neck, which may be used to preoperatively select a subpopulation of patients requiring central neck dissection, including those with macroscopic central nodal metastases. However, central neck dissection has been associated with potential surgical morbidity [18,19]. Because paratracheal metastases of unilateral PTC lesions on the contralateral side are uncommon [16,18,19], central neck dissection may spare the contralateral paratracheal area, thus minimizing surgical morbidities.…”

“…However, central neck dissection has been associated with potential surgical morbidity [18,19]. Because paratracheal metastases of unilateral PTC lesions on the contralateral side are uncommon [16,18,19], central neck dissection may spare the contralateral paratracheal area, thus minimizing surgical morbidities. However, patients with macroscpic nodal diseases on US may undergo bilateral central neck dissection.…”

Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection

“…6 Central neck dissection (CND) may prevent central neck recurrence, but bilateral CND is associated with significant morbidity, especially postoperative hypoparathyroidism. [7][8][9] Despite being selflimiting in most patients, symptomatic hypocalcemia is of particular concern because of its delayed manifestation and the consequent need for prolonged patient hospitalization or readmission.…”

Safety and Prognostic Impact of Prophylactic Level VII Lymph Node Dissection for Papillary Thyroid Carcinoma

“…In this study, the permanent hypoparathyroidism was documented in 6.5% for group A and 9.4% for group B patients which was much less than that reported by Tartaglia et al, 2014 25.4% of patients who underwent TT + CND, within the range reported by White et al, 20070-14.3% while Pereira et al, 2005Choi et al, 2011;Popadich et al,2011;Wang et al, 2013;and Lee et al, 2015 reported only 2%, 3% ,0.8%, 4.6% and 3.3% permanent hypoparathyroidism respectively. Temporary hypoparathyroidism was (Tartaglia et al, 2014), 6% (Wang et al, 2013) and 9.7% (Popadich et al, 2011) but sometimes as high as 60% (Pereira et al, 2005). In this study, the permanent VCD was documented in 3.2% in group A and 6.3% in group B which was within the reported range (0-12%) in other studies (Choi et al, 2011;Hughes and Doherty, 2011;Popadich et al, 2011;Giordano et al, 2012;Wang et al, 2013;Tartaglia et al, 2014;Lee et al, 2015), while temporary VCD was reported to be 12.9% in group A and 9.4% in group B which was slightly higher than the reported range (0.4-9%) in other studies (Pereira et al, 2005;Popadich et al, 2011;Wang et al, 2013;Tartaglia et al, 2014;Lee et al, 2015).…”

“…Temporary hypoparathyroidism was (Tartaglia et al, 2014), 6% (Wang et al, 2013) and 9.7% (Popadich et al, 2011) but sometimes as high as 60% (Pereira et al, 2005). In this study, the permanent VCD was documented in 3.2% in group A and 6.3% in group B which was within the reported range (0-12%) in other studies (Choi et al, 2011;Hughes and Doherty, 2011;Popadich et al, 2011;Giordano et al, 2012;Wang et al, 2013;Tartaglia et al, 2014;Lee et al, 2015), while temporary VCD was reported to be 12.9% in group A and 9.4% in group B which was slightly higher than the reported range (0.4-9%) in other studies (Pereira et al, 2005;Popadich et al, 2011;Wang et al, 2013;Tartaglia et al, 2014;Lee et al, 2015).…”